1. Scrip
  2. >>Therapy Areas

Lupin makes at-risk launch of metformin ER in the US

 
• By Anju Ghangurde

Lupin has launched metformin hydrochloride extended-release 500mg and 1,000mg tablets at risk in the US. The products are generic versions of Watson's diabetes medication Fortamet, which is marketed by Sciele Pharma (now part of Shionogi) in the US.

Lupin has launched metformin hydrochloride extended-release 500mg and 1,000mg tablets at risk in the US. The products are generic versions of Watson's diabetes medication Fortamet, which is marketed by Sciele Pharma (now part of Shionogi) in the US.

Lupin said that it had launched its generic Fortamet on 30 September, adding that Shionogi and Watson had filed a...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

More from Therapeutic Category

Spyre Takes Aim At Roche And J&J In Inflammatory Diseases

 
• By Andrew McConaghie

The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.

Draig Is All Fired Up To Transform Neuropsychiatric Field

 
• By Kevin Grogan

Wales-based group launches with $140m series A.

Immuneering Could Partner Atebimetinib Or Go It Alone After Phase IIa Success

 
• By Alaric DeArment

CEO Ben Zeskind said all options are on the table after atebimetinib showed impressive results in pancreatic cancer.